📋 Tender Overview
IATI identifier 46002-P-EG-BB0-008
Country Egypt
Sector Industry, Minning & Quarrying
High 5 Industrialize Africa
Sovereign / Non-Sovereign Non-sovereign
Environmental Category [1] High Risk
Gender Marker System Categorization [GEN II] Gender Outcomes
Commitment (UA) 12,437,708
Project General Description
A long-term investment program for the renovation and expansion of Minapharm’s pharmaceutical operations aimed at developing, manufacturing and commercializing biosimilars foroncology and autoimmunity-based diseases. The investment program includes (i) product development, construction, and the equipping of a second drug substance and drug product biotechnology facility in Cairo, Egypt and (ii) renovation of existing production lines.
Project Objectives
The project is a long-term investment program to develop, manufacture and commercialize additional biosimilar monoclonal antibodies targeting oncology and autoimmunity-based diseases, which is a highly unmet medical need in Africa. With the objective of building a biological Active Pharmaceutical Ingredients (API) hub to serve Africa and the Middle East (MEA) region, the investment program includes: (i) product development, construction, and the equipping of a second drug substance and drug product biotechnology facility in Cairo, Egypt ( XpandC ) and (ii) renovation of existing production lines.
Beneficiaries
Minapharm's XpandC manufacturing facility is designed to transform the biotechnological landscape in Africa, focusing on both research and production of therapeutic proteins for prevalent diseases. Located in Cairo, the facility aims to provide accessible and affordable healthcare solutions while generating foreign currency to benefit the Egyptian economy. Minapharm employs over 2,000 skilled professionals and invests in training programs to develop future talent, offering internships to empower students and young professionals. The company is committed to gender equality and fosters gender balance within its workforce. Additionally, Minapharm prioritizes sustainability by investing in energy-efficient technologies and implementing practices that reduce environmental impact, such as using renewable energies and optimizing waste management.
